CODE: TCS/16/31 RESEARCH

PROJECT BRIEFING KEY FINDINGS In the very early phase Bevacizumab does not alter resting or stimulated blood flow nor levels of the hormones ET1 or tPA The ET1 blocker drug BQ123 does not alter stimulated blood flow in response to bradykinin a hormone that causes blood vessel relaxation when bevacizumab is present

Embed this Presentation

Download Notice

Download Presentation The PPT/PDF document "CODE: TCS/16/31 RESEARCH" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.